Glossary of terms and abbreviations

Alternative performance measures

In reporting financial information, the Group presents alternative performance measures (APMs) which are not defined or specified under the requirements of IFRS. The Group believes that these APMs, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The alternative performance measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures. The key APMs that the Group uses are outlined below.

APM	Closest equivalent IFRS measure	Reconciling items to IFRS measure	Definition and purpose
Income statement measures
Adjusted earnings before interest, tax, depreciation and amortisation (Adjusted EBITDA)	Profit/(loss) before income tax	Finance costs, income tax expense, depreciation and amortisation, remeasurement of provisions, other income and expenses.	Used to help assess current operational performance excluding the impacts of non-cash sunk costs (i.e. depreciation and amortisation from initial investment in tangible and intangible assets). It is a measure that management uses internally to assess the performance of the Group’s segments and make decisions on the allocation of resources.
Adjusted earnings before interest, tax, depreciation and amortisation and research and development (Adjusted EBITDAR)	Profit/(loss) before income tax	Finance costs, income tax expense, depreciation and amortisation, remeasurement of provisions, other income and expenses and costs associated with product development activities.	Used to assess the Group's performance excluding non-operating expenditure, finance costs, depreciation and amortisation, taxation expense and product development activities. Included as a metric for LTVR targets in 2023.
Adjusted earnings before interest, tax, research and development (Adjusted EBITRD)	Profit/(loss) before income tax	Finance costs, income tax expense, remeasurement of provisions, other income and expenses and costs associated with product development activities.	Used to assess the Group's performance excluding non-operating expenditure, finance costs, taxation expense and product development activities. Included as a metric for LTVR targets in 2022.
Balance sheet measures
Net tangible asset per share	None	Net assets excluding intangible assets, deferred tax assets and right-of-use assets divided by the Group's weighted average number of ordinary shares on issue	Disclosed in the Group's Appendix 4E as required by Rule 4.3A of the ASX listing rules.

Abbreviations used in Annual Report

We have outlined below the meaning of various abbreviations or acronyms used in the Annual Report.

Abbreviations

Abbreviation	Term
AASB	Australian Accounting Standards Board
ADS	American Depositary Share
AHPRA	Australian Health Practitioner Regulation Agency
AI	Artificial intelligence
AML	Acute myeloid leukaemia
APPI	Japanese Act on the Protection of Personal Information
ARC	Audit and Risk Committee
ASIC	Australian Securities and Investments Commission
ASX	Australian Securities Exchange
AutoML	Automatic machine-learning
BBB	Blood-brain barrier
BLA	Biologics License Application
BMC	Bone marrow conditioning
CAIX	Carbonic anhydrase IX
ccRCC	Clear cell renal cell carcinoma
CD66	Cluster of differentiation 66
CDO	Group Chief Development Officer
CDSS	Clinical decision support software
CE	Conformité Européenne Mark
CMO	Group Chief Medical Officer
CNS	Central nervous system
DNA-PK	DNA-dependent protein kinase
EAP	Expanded access program
EBRT	External beam radiation therapy
ERMF	Enterprise Risk Management Framework
ESG	Environment, Social and Governance
FANC	Belgian Federal Agency for Nuclear Control
FDA	United States Food and Drug Administration
GBM	Glioblastoma multiforme
GCP	Good Clinical Practice
GDP	Good Distribution Practice
GDPR	General Data Protection Regulation
GET	Group Executive Team
GHG	Greenhouse gas
GLF	Global Leadership Forum
GLP	Good Laboratories Practice
GMP	Good Manufacturing Practice
GRC	Governance, Risk and Compliance
GSRC	Global Safety Review Committee
HIPAA	US Health Insurance Portability and Accountability Act
HSCT	Hematopoietic stem cell transplant
HSWE	Health, safety, wellbeing and environment
IAEA	International Atomic Energy Agency
ICRP	International Commission of Radiological Protection
IIT	Investigator initiated trial
IND	Investigational new drug
IPO	Initial Public Offering
ISMS	Information Security and Information Management
ISSB	International Sustainability Standards Board
KMP	Key management personnel
LAT1 & 2	L-type amino acid transporters 1 & 2
MBS	Medicare Benefits Schedule
mCRPC	Metastatic castration-resistant prostate cancer
MM	Multiple myeloma
MRI	Magnetic resonance imaging
NDA	New Drug Application
NED	Non-Executive Director
NPP	Named patient program
ODD	Orphan drug designation
PCNRC	People, Culture, Nomination and Remuneration Committee
PDGFRα	Platelet-derived growth factor receptor alpha
PMDA	Pharmaceuticals and Medical Devices Agency (Japan)
PoC	Proof-of-concept
PSA	Prostate-specific antigen
PSMA	Prostate-specific membrane antigen
PSMA-PET	Prostate-specific membrane antigen imaging with positron emission tomography
QMS	Quality Management System
QSEB	Quality and Safety Evaluation Board
R&D	Research and development
R&I	Research and Innovation
rADC	Radio antibody-drug conjugate
REACH	Registration, Evaluation and Authorisation of Chemicals
RGS	Radio-guided surgery
SALA	Systemic amyloid light chain amyloidosis
SLN	Sentinel lymph node
SoC	Standard of care
SOP	Standard operating procedure
SPECT	Single photon emission computed tomography
STS	Soft tissue sarcoma
TAT	Targeted alpha therapy
TGA	Therapeutic Goods Administration (Australia)
TMS	Telix Manufacturing Solutions
TNBC	Triple-negative breast cancer
UN	The United Nations
VHL	Von Hippel Landau